Abrégé

A method of treating non-melanoma skin cancer or a precancerous skin condition in a patient is provided. The method includes applying to a lesion on the patient a topical composition including 5-aminolevulinic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient; incubating the topical composition on the lesion; and illuminating the lesion with a blue light source.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure is directed to polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

Hd8HdRR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• C07D 487/04 - Systèmes condensés en ortho
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Abrégé

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof. Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Abrégé

A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/75 - Polymères d'hydrocarbures d'éthène
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors

Produits et services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Produits et services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Produits et services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Produits et services

(1) Medical device for crushing applicators containing pharmaceutical preparations

Produits et services

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders

Abrégé

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07D 231/10 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
• C07D 487/04 - Systèmes condensés en ortho
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
• A61P 25/22 - Anxiolytiques
• A61P 25/24 - Antidépresseurs

Abrégé

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Abrégé

yl)-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• C07D 487/04 - Systèmes condensés en ortho

Abrégé

A method of treating non-melanoma skin cancer in a patient in need thereof is provided. The method includes administering a hedgehog pathway inhibitor to the patient and applying to a region of skin on the patient, a topical composition comprising 5-aminolevulinic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The method further includes incubating the topical composition on the region of skin; and illuminating the region of skin with a light source at an irradiance density of 20 mW/cm2.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61P 35/00 - Agents anticancéreux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61N 5/067 - Thérapie par radiations utilisant un rayonnement lumineux utilisant un rayonnement laser

Produits et services

(1) Photodynamic and photodetection pharmaceutical preparations for the treatment of dermatological conditions (2) Medical devices and apparatuses for photodynamic therapy and photodetection for use in conjunction with pharmaceutical products and preparations (1) Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare (2) Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders; providing medical information for physicians, pharmacists, and patients in the field of dermatology; providing medical information regarding pharmaceutical products for the treatment and prevention dermatology, and skin diseases and disorders

Abrégé

D-serine.

Classes IPC  ?

• C07C 227/32 - Préparation d'isomères optiques par synthèse stéréospécifique
• C07D 263/04 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques

Abrégé

The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/5685 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone ayant un groupe oxo en position 17, p. ex. androstérone
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 487/04 - Systèmes condensés en ortho

Abrégé

Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods and topical compositions for use in photodynamic therapy are disclosed, in which the topical composition is applied to the affected area of a patient for a period in the range of about 15 minutes to about 10 hours.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Produits et services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Produits et services

(1) Business administration of pharmacy reimbursement programs and services; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies (2) Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status and related information for others (3) Distribution services, namely, delivery of pharmaceutical products. (4) Patient support and assistance in connection with pharmaceutical services, namely, providing medical information about pharmaceuticals

Abrégé

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho

Abrégé

A method of treating a JAK-inhibition-responsive condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of a compound represented by structural formulas (I) or (II), as described herein, or a pharmaceutically acceptable salt thereof. A method of treating a JAK-inhibition-responsive condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of a compound represented by structural formulas (I) or (II), as described herein, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles

Abrégé

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 309/65 - Esters d'acides sulfoniques ayant des atomes de soufre de groupes sulfo estérifiés liés à des atomes de carbone acycliques d'un squelette carboné saturé
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Produits et services

Medical device for crushing applicators containing pharmaceutical preparations

Produits et services

(1) Non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions.

Produits et services

Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare Photodynamic and photodetection pharmaceutical preparations for the treatment of dermatological conditions Medical devices and apparatuses for photodynamic therapy and photodetection for use in conjunction with pharmaceutical products and preparations Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders; providing medical information for physicians, pharmacists, and patients in the field of dermatology; providing medical information regarding pharmaceutical products for the treatment and prevention dermatology, and skin diseases and disorders

Produits et services

Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders

Produits et services

Business administration of pharmacy reimbursement programs and services; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status and related information for others Distribution services, namely, delivery of pharmaceutical products Patient support and assistance in connection with pharmaceutical services, namely, providing medical information about pharmaceuticals

Produits et services

Pharmaceutical preparations for the treatment of autoimmune, gastrointestinal, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for the treatment of hair loss disorders; pharmaceutical preparations, namely, medicated dermatological preparations; pharmaceutical preparations for the treatment of alopecia areata, atopic dermatitis, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Produits et services

non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions

Abrégé

A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Produits et services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Produits et services

(1) Analgesics; antacids; anti-cancer preparations; antibiotics; anticoagulants; anticonvulsants; antidepressants; antidiabetic preparations; antifungal preparations; antihypertensives; antiseptic preparations; antivirals; calcium channel blockers; corticosteroids; laxatives; nausea treatment preparations; pharmaceutical preparations for controlling cholesterol; pharmaceutical preparations for maintaining normal blood pressure and heart function; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of iron deficiency and anemia in humans; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of muscle spasms, tremors and pain; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations namely, anti-inflammatories; psychiatric pharmaceutical preparations for the prevention and treatment of mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; steroids; tumor suppressing agents

Produits et services

(1) Downloadable mobile applications for patients and parents to enter patient daily journal entries, track daily skincare routines, upload photos, and find a dermatologist; downloadable mobile applications to provide healthy tips in the field of acne and skincare

Produits et services

(1) Providing a website and online social media featuring educational information in the field of the diagnosis, prevention, and treatment of skin conditions, including acne

Abrégé

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof. Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Abrégé

Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Abrégé

The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• C07D 487/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/5685 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone ayant un groupe oxo en position 17, p. ex. androstérone
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique

Abrégé

Certain aspects of the present invention are directed to improved processes for preparing enantiomerically enriched intermediates for the synthesis of ruxolitinib and deuterated forms of ruxolitinib. Certain aspects are also directed to deuterated intermediates useful in the synthesis of deuterated forms of ruxolitinib. Certain aspects are also directed to reaction mixtures for preparing enantiomerically enriched intermediates useful in the synthesis of ruxolitinib and deuterated forms of ruxolitinib.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• B01J 31/40 - Régénération ou réactivation

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/75 - Polymères d'hydrocarbures d'éthène
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors

Produits et services

(1) Printed materials, namely, patient guides, consent forms and pregnancy prevention checklists, providing information relating to the treatment of dermatological conditions (1) Educational services to patients in the treatment of dermatological conditions (2) Medical services for the treatment of dermatological conditions

Abrégé

Improved processes and intermediates for preparing ruxolitinib, deuterated analogs of ruxolitinib, and other JAK inhibitors are disclosed.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle

Produits et services

Providing a website featuring educational information in the field to medical diagnosis, prevention, and treatment of skin conditions, particularly, acne

Produits et services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne

Abrégé

A method of performing photodynamic therapy is provided. The method includes applying, to the skin of a patient, a topical composition. The topical composition includes 5-aminolevulinic acid (ALA) hydrochloride, and a vehicle comprising at least one chelating agent to enhance accumulation of protoporphyrin IX (PpIX) in the skin. The method further includes incubating the topical composition, and following incubation, applying, to the skin, heat from a heat source for at least a first time period.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61F 7/00 - Appareils de chauffage ou de refroidissement pour traitement médical ou thérapeutique du corps humain
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés

Abrégé

Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods and topical compositions for use in photodynamic therapy are disclosed, in which the topical composition is applied to the affected area of a patient for a period in the range of about 15 minutes to about 10 hours.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Produits et services

(1) Medical device for treating and diagnosing dermatological conditions.

Abrégé

Dermal neurofibroma, in particular Neurofibromatosis Type I (NF1) leads to progressive tumor proliferation with no known mechanism to inhibit growth. The present invention relates to the use of photodynamic therapy (PDT) for attenuating tumor growth in NF1 patients. More particularly the invention provides a method of treating dermal neurofibroma comprising topically applying a pharmaceutical composition comprising a photosensitizer to the affected area of a patient, incubating the affected area, and irradiating the affected area with a light of suitable wavelength as per the photosensitizer used, wherein the treatment is characterized by inhibiting the progression of tumor growth and/or reduction in tumor size and/or increased mortality rate of the neurofibroma cell.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61P 35/00 - Agents anticancéreux

Abrégé

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/75 - Polymères d'hydrocarbures d'éthène

Abrégé

This present invention and its embodiments relates to methods for reducing pain during photodynamic therapy of actinic keratosis. The present invention also relates to methods of treating actinic keratosis with reduced pain during photodynamic therapy of actinic keratosis.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention is directed to methods of treating diseases and disorders of the skin (e.g., acne) with heat-enabled photodynamic therapy (HEPT).

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61P 17/10 - Antiacnéïques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/107 - Émulsions
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique

Abrégé

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]

Abrégé

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 309/65 - Esters d'acides sulfoniques ayant des atomes de soufre de groupes sulfo estérifiés liés à des atomes de carbone acycliques d'un squelette carboné saturé
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Produits et services

Medical device for treating and diagnosing dermatological conditions

Abrégé

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.

Classes IPC  ?

• C07C 227/32 - Préparation d'isomères optiques par synthèse stéréospécifique
• C07D 263/04 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques

Abrégé

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/18 - Sulfamides
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
• C07C 69/675 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés d'acides hydroxycarboxyliques saturés
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino

Abrégé

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie

Produits et services

(1) Printed materials, namely patient guides, consent forms and pregnancy prevention checklists, providing information relating to the treatment of dermatological conditions, none of the foregoing in the nature of a magazine in the fields of nursing and healthcare. (1) Educational services to patients in the treatment of dermatological conditions (2) Medical services for the treatment of dermatological conditions

Abrégé

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/75 - Polymères d'hydrocarbures d'éthène

Abrégé

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Classes IPC  ?

• C07C 59/115 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal contenant des atomes d'halogène
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
• C07C 69/67 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
• A61K 31/225 - Acides polycarboxyliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07C 59/125 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes éther, des groupes , des groupes ou des groupes
• C07C 69/675 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés d'acides hydroxycarboxyliques saturés
• C07C 69/708 - Éthers

Abrégé

Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

This invention relates to novel α-tocotrienol quinones of Formula I: (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering Vitamin E.

Classes IPC  ?

• C07C 50/06 - Quinones à structure quinoïde monocyclique avec insaturation autre que celle de la structure quinoïde
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/75 - Polymères d'hydrocarbures d'éthène

Produits et services

Pharmaceutical preparations for the treatment of autoimmune, gastrointestinal, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for the treatment of hair loss disorders; pharmaceutical preparations, namely, medicated dermatological preparations; pharmaceutical preparations for the treatment of alopecia areata, atopic dermatitis, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Abrégé

An applicator for dispensing a solution having two or more components includes a hollow body having a head provided at one end of the hollow body for dispersion of the solution and a breaking mechanism attached to the hollow body. The breaking mechanism includes at least one projection extendable into an interior of the hollow body. The applicator further includes a plurality of ampoules placed in the interior of the hollow body. The plurality of ampoules contains the two or more components. Upon activation of the breaking mechanism, the at least one projection applies a force to the plurality of ampoules such that the plurality of ampoules break and release the two or more components to form the solution.

Classes IPC  ?

• A61M 35/00 - Dispositifs pour appliquer des agents, p. ex. des remèdes, sur le corps humain
• A61J 1/06 - Ampoules ou cartouches
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue

Abrégé

A method of administering 5-aminolevulinic acid (ALA) to a patient uses an adjustable illuminator for photodynamically diagnosing or treating a surface and which includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Abrégé

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• C07C 59/01 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes hydroxyle ou O-métal
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 69/675 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés d'acides hydroxycarboxyliques saturés
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino

Produits et services

Medical device for crushing applicators containing pharmaceutical preparations

Produits et services

Medical device for crushing applicators containing pharmaceutical preparations

Produits et services

Non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions

Abrégé

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Produits et services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Abrégé

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Produits et services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Produits et services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Produits et services

Pharmaceutical and medicinal preparation for treatment of dermatological conditions

Produits et services

Business administration of pharmacy reimbursement programs and co-pay support programs; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status in the field of medical and pharmaceutical insurance and related information for others; financial administration of pharmacy reimbursement program and co-pay support programs

Produits et services

Business administration of pharmacy reimbursement programs and co-pay support programs; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status in the field of medical and pharmaceutical insurance and related information for others; financial administration of pharmacy reimbursement program and co-pay support programs

Abrégé

1 receptor agonist that also has NMDA antagonist activity.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• C07D 221/28 - Morphinanes
• A61P 25/08 - AntiépileptiquesAnticonvulsivants
• A61P 25/16 - Antiparkinsoniens
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07D 471/08 - Systèmes pontés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles

Produits et services

(1) Kits for the preparation of radiolabeled pharmaceuticals, namely, radioactive compounds used for diagnostic or therapeutic purposes for use in in vivo diagnostic imaging procedures; Radioactive pharmaceutical agents, namely, pharmaceutical drugs containing radioactive isotopes for use in in vivo diagnostic imaging

Produits et services

Kits for the preparation of radiolabeled pharmaceuticals for use in in vivo diagnostic imaging procedures; Radioactive pharmaceutical agents for use in in vivo diagnostic imaging

Abrégé

The present invention in one embodiment provides a method of treating Leber's hereditary optic neuropathy, comprising administering to a subject in need of such treatment a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

Classes IPC  ?

• C07C 50/28 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone à structure quinoïde monocyclique
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/75 - Polymères d'hydrocarbures d'éthène

Abrégé

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/75 - Polymères d'hydrocarbures d'éthène

Abrégé

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.

Classes IPC  ?

• C07C 323/22 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique

Abrégé

This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• C07D 221/28 - Morphinanes
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• C07D 471/08 - Systèmes pontés
• A61P 25/16 - Antiparkinsoniens
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 25/08 - AntiépileptiquesAnticonvulsivants
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

Classes IPC  ?

• C07C 50/28 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone à structure quinoïde monocyclique
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• C07D 473/06 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 deux atomes d'oxygène avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés en position 1 ou 3